Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 18, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 21, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001437749-26-004947
Filed / recorded
Feb 21, 2026, 6:28 AM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
PUMA BIOTECHNOLOGY, INC.
Issuer CIK
1401667
Ticker
PBYI
Reporting person
Douglas M Hunt
Relationship
Officer
Officer title
See Remarks
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Feb 18, 2026
Transaction code
A
Shares / units
70,321
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
70,321
Ownership form
Direct
Amendment
No
Footnotes from the filing
Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.